-
公开(公告)号：US08859540B2
公开(公告)日：2014-10-14
申请号：US11879708
申请日：2007-07-18
Applicant: Chris Rundfeldt , Rita Dost , Wolfgang Loscher , Andrea Tipold , Klaus Unverferth , Hans-Joachim Lankau
Inventor： Chris Rundfeldt , Rita Dost , Wolfgang Loscher , Andrea Tipold , Klaus Unverferth , Hans-Joachim Lankau
IPC: A61K31/535 , A61K31/41
CPC classification number: A61K31/5377 , A61K31/515 , C07D233/02 , A61K2300/00
Abstract: The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs.
Abstract translation: 本发明涉及取代的二氢咪唑啉酮，特别是[1-（4-氯苯基）-4-（4-吗啉基）-2,5-二氢-1H-咪唑-2-酮]（AWD 131-138）或 其生理上可接受的盐用于治疗狗中的癫痫。
-
2.发明申请Potassium Channel Activators for the Prevention and Treatment of Dystonia and Dystonia-Like Symptoms 审中-公开钾通道激活剂用于预防和治疗肌张力障碍和肌张力障碍样症状公开(公告)号：US20090137641A1
公开(公告)日：2009-05-28
申请号：US12296960
申请日：2007-04-30
Applicant: Chris Rundfeldt , Angelika Richter
Inventor： Chris Rundfeldt , Angelika Richter
IPC: A61K31/44 , A61K31/24 , A61K31/404
CPC classification number: A61K31/196 , A61K31/44
Abstract: The present invention is directed to the prevention, reversal and medical treatment of dystonia and dyskinesia as well as other diseases related to movement disorders, both in human beings and animals by administering a neuronal potassium channel opener such as flupirtine, retigabine or maxipost.
Abstract translation: 本发明涉及通过施用神经元钾通道开放剂如氟吡汀，瑞替加林或上皮ost素来预防，逆转和治疗肌张力障碍和运动障碍以及与运动障碍有关的其它疾病，在人和动物中。
-
公开(公告)号：US07211583B2
公开(公告)日：2007-05-01
申请号：US10826136
申请日：2004-04-16
Applicant: Nobert Höfgen , Hildegard Kuss , Matthias Olbrich , Ute Egerland , Chris Rundfeldt , Karin Steinike , Rudolf Schindler
Inventor： Nobert Höfgen , Hildegard Kuss , Matthias Olbrich , Ute Egerland , Chris Rundfeldt , Karin Steinike , Rudolf Schindler
IPC: C07D471/02 , A61K31/437
CPC classification number: C07D471/04
Abstract: The invention relates to substituted 7-azaindoles, process for their preparation, pharmaceutical preparations which comprise these compounds, and the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active ingredients for the treatment of disorders which can be influenced by inhibition of phosphodiesterase 4 activity in particular in immunocompetent cells (e.g. macrophages and lymphocytes) by the compounds of the invention.
Abstract translation: 本发明涉及取代的7-氮杂吲哚，其制备方法，包含这些化合物的药物制剂以及作为磷酸二酯酶4抑制剂的这些化合物的药物用途，作为治疗可受抑制影响的病症的活性成分 的磷酸二酯酶4活性，特别是在本发明化合物的免疫活性细胞（例如巨噬细胞和淋巴细胞）中。
-
4.发明授权Use of 2-4-amino-4-(4-fluorobenzylamino) (-1-ethoxy-carbonylaminobenzene for the prophylaxis and treatment of the neurodegenerative disorders 失效2-氨基-4-（4-氟苄基氨基）（-1-乙氧羰基氨基苯）用于预防和治疗神经变性疾病
公开(公告)号：US5852053A
公开(公告)日：1998-12-22
申请号：US736166
申请日：1996-10-28
Applicant: Angelika Rostock , Chris Rundfeldt , Christine Tober , Reni Bartsch
Inventor： Angelika Rostock , Chris Rundfeldt , Christine Tober , Reni Bartsch
CPC classification number: A61K31/27 , Y10S514/903
Abstract: The use of the compound I ##STR1## or its pharmaceutically utilizable salts for the propylaxis and treatment of the squelae of chronic reduced cerebral blood supply, in particular of stroke, and for the treatment of nuerodegenerative disorders is claimed.
Abstract translation: 要求使用化合物I IMAMA或其药学上可利用的盐用于丙氨酸和治疗慢性降低的脑血供，特别是中风和用于治疗复苏性疾病的静脉。
-
5.发明授权Use of 4-amino-4-(4-fluorobenzylamino)-1-ethoxy-carbonylaminobenzene for the prophylaxis and treatment of reduced cerebral blood supply 失效使用2-氨基-4-（4-氟苄基氨基）-1-乙氧羰基氨基苯预防和治疗脑血供减少
公开(公告)号：US5849789A
公开(公告)日：1998-12-15
申请号：US937420
申请日：1997-09-25
Applicant: Angelika Rostock , Chris Rundfeldt , Christine Tober , Reni Bartsch
Inventor： Angelika Rostock , Chris Rundfeldt , Christine Tober , Reni Bartsch
CPC classification number: A61K31/27 , Y10S514/903
Abstract: The use of the compound I ##STR1## or its pharmaceutically utilizable salts for the propylaxis and treatment of the sequel of chronic reduced cerebral blood supply, in particular of stroke, and for the treatment of neurodegenerative disorders is claimed.
Abstract translation: 本发明要求使用化合物I IMAGE或其药学上可用的盐作为丙氨酸并治疗慢性降低的脑血供，特别是中风，以及用于治疗神经变性疾病的续作。
-
Patent Agency Ranking
公开(公告)号：US08962617B2
公开(公告)日：2015-02-24
申请号：US13616440
申请日：2012-09-14
Applicant: Chris Rundfeldt , Rita Dost , Wolfgang Loscher , Andrea Tipold , Klaus Unverferth , Hans-Joachim Lankau
Inventor： Chris Rundfeldt , Rita Dost , Wolfgang Loscher , Andrea Tipold , Klaus Unverferth , Hans-Joachim Lankau
IPC: A61K31/535 , A61K31/41 , A61K31/515 , A61K31/5377
CPC classification number: A61K31/5377 , A61K31/515 , C07D233/02 , A61K2300/00
Abstract: The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs.
Abstract translation: 本发明涉及取代的二氢咪唑啉酮，特别是[1-（4-氯苯基）-4-（4-吗啉基）-2,5-二氢-1H-咪唑-2-酮]（AWD 131-138）或 其生理上可接受的盐用于治疗狗中的癫痫。
-
公开(公告)号：US20130065898A1
公开(公告)日：2013-03-14
申请号：US13616440
申请日：2012-09-14
Applicant: CHRIS RUNDFELDT , Rita Dost , Wolfgang Loscher , Andrea Tipold , Klaus Unyerferth , Hans-Joachim Lankau
Inventor： CHRIS RUNDFELDT , Rita Dost , Wolfgang Loscher , Andrea Tipold , Klaus Unyerferth , Hans-Joachim Lankau
IPC: A61K31/5377 , A61P25/08
CPC classification number: A61K31/5377 , A61K31/515 , C07D233/02 , A61K2300/00
Abstract: The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs.
-
8.发明申请Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor 审中-公开用对苯并二氮杂受体的α3亚基具有选择性的化合物治疗或预防中枢神经系统障碍的方法公开(公告)号：US20080114032A1
公开(公告)日：2008-05-15
申请号：US11978362
申请日：2007-10-29
Applicant: Barbara Langen , Chris Rundfeldt , Rita Dost , Hartmut Luddens , Holger Rabe
Inventor： Barbara Langen , Chris Rundfeldt , Rita Dost , Hartmut Luddens , Holger Rabe
IPC: A61K31/4164 , A61P25/00 , A61K31/454
CPC classification number: A61K31/4164 , A61K31/4166 , A61K31/454 , A61K31/5377
Abstract: The present invention relates to the use of 1-ar(alk)ylimidazolin-2-ones which contain a disubstituted amine radical in the 4-position for the treatment or prevention of central nervous system disorders including depression, anxiety, movement disorders, and especially dystonia, and psychotic disorders, and especially schizophrenia and psychotic symptoms associated to other mental disorders.
Abstract translation: 本发明涉及在4-位含有二取代的胺基的1-芳（烷基）基咪唑啉-2-酮的用途，用于治疗或预防中枢神经系统疾病，包括抑郁，焦虑，运动障碍，特别是 肌张力障碍和精神病，特别是与其他精神障碍相关的精神分裂症和精神病症状。
-
公开(公告)号：US20080027057A1
公开(公告)日：2008-01-31
申请号：US11879708
申请日：2007-07-18
Applicant: Chris Rundfeldt , Rita Dost , Wolfgang Loscher , Andrea Tipold , Klaus Unverferth , Hans-Joachim Lankau
Inventor： Chris Rundfeldt , Rita Dost , Wolfgang Loscher , Andrea Tipold , Klaus Unverferth , Hans-Joachim Lankau
IPC: A61K31/5375 , A61P25/00
CPC classification number: A61K31/5377 , A61K31/515 , C07D233/02 , A61K2300/00
Abstract: The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1 H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs.
Abstract translation: 本发明涉及取代的二氢咪唑酮，特别是[1-（4-氯苯基）-4-（4-吗啉基）-2,5-二氢-1H-咪唑-2-酮]（AWD 131-138） 或其生理上可接受的盐用于治疗狗中的癫痫。
-
10.发明申请Use of the non-opiate analgesic drug flupirtine of the treatment of overactive bladder and associated diseases including urge incontinence, urinary flow problems as a result of prostate hyperplasia and irritable bowl syndrome 失效使用非阿片类镇痛药物氟吡汀治疗膀胱过度活动和相关疾病，包括急迫性尿失禁，前列腺增生和肠易激综合征导致的尿流问题公开(公告)号：US20060173052A1
公开(公告)日：2006-08-03
申请号：US11336406
申请日：2006-01-20
Applicant: Chris Rundfeldt , Hildegard Kuss , Regina Draheim
Inventor： Chris Rundfeldt , Hildegard Kuss , Regina Draheim
IPC: A61K31/44
CPC classification number: A61K31/44 , Y10S514/867
Abstract: The present invention is directed to the prevention, reversal and medical treatment of lower urinary tract dysfunction including bladder instability and other related diseases as described below including urinary flow problems, urgency and incontinence as a result of prostate hyperplasia (BPH) and to the prevention, reversal and medical treatment of irritable bowl syndrome (IBS) with special focus on the diarrhea-predominant and mixed diarrhea-constipation type IBS, both in human beings and animals.
Abstract translation: 本发明涉及如下所述的包括膀胱不稳定性和其他相关疾病在内的下尿路功能障碍的预防，逆转和治疗，包括由前列腺增生（BPH）引起的尿流问题，紧急性和失禁以及预防， 急性肠易激综合征（IBS）的逆转和治疗，特别关注腹泻主要和混合型腹泻便秘型IBS，人类和动物。
-
-
-
-
-
-
-
-
-
Search Results
30
records
(took 0.018 seconds)
